Analysts Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Price Target at $10.78

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has been assigned a consensus rating of “Hold” from the ten ratings firms that are currently covering the stock, MarketBeat reports. Seven analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $10.78.

A number of research firms have commented on ZNTL. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, August 12th. Oppenheimer restated an “outperform” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Jefferies Financial Group restated a “hold” rating and set a $6.00 price objective (down previously from $42.00) on shares of Zentalis Pharmaceuticals in a research report on Tuesday, June 18th. Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective for the company in a research report on Monday, August 12th. Finally, Morgan Stanley restated an “equal weight” rating and set a $8.00 price objective (down previously from $38.00) on shares of Zentalis Pharmaceuticals in a research report on Tuesday, June 18th.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several institutional investors have recently made changes to their positions in ZNTL. Los Angeles Capital Management LLC purchased a new stake in Zentalis Pharmaceuticals in the 1st quarter worth about $606,000. XTX Topco Ltd lifted its stake in shares of Zentalis Pharmaceuticals by 1,581.9% during the 2nd quarter. XTX Topco Ltd now owns 178,465 shares of the company’s stock worth $730,000 after acquiring an additional 167,854 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Zentalis Pharmaceuticals by 20.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock valued at $54,999,000 after acquiring an additional 585,644 shares during the period. Decheng Capital LLC grew its position in Zentalis Pharmaceuticals by 46.2% in the 2nd quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock valued at $12,558,000 after acquiring an additional 970,859 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in Zentalis Pharmaceuticals by 152.6% in the second quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock worth $2,706,000 after purchasing an additional 399,745 shares during the period.

Zentalis Pharmaceuticals Stock Up 1.7 %

NASDAQ:ZNTL opened at $2.99 on Thursday. The business’s 50-day simple moving average is $3.36 and its two-hundred day simple moving average is $7.23. The stock has a market cap of $212.62 million, a PE ratio of -1.10 and a beta of 1.70. Zentalis Pharmaceuticals has a 52 week low of $2.83 and a 52 week high of $19.14.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Friday, August 9th. The company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.40). During the same quarter last year, the company earned ($1.85) earnings per share. Sell-side analysts anticipate that Zentalis Pharmaceuticals will post -3.02 earnings per share for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.